Preventing Herpes Zoster through Vaccination

Ophthalmology

Volumn 115, Issue 2 SUPPL., 2008, Pages

  Gelb, Lawrence D ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; VARICELLA ZOSTER VACCINE;

ARTICLE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE CONTROL; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; HERPES ZOSTER; HERPES ZOSTER OPHTHALMICUS; HUMAN; INJECTION SITE PAIN; INJECTION SITE WARMTH; NONHUMAN; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; PRURITUS; QUALITY ADJUSTED LIFE YEAR; SWELLING; VACCINATION;

COST-BENEFIT ANALYSIS; HERPES ZOSTER OPHTHALMICUS; HERPES ZOSTER VACCINE; HUMANS; NEURALGIA, POSTHERPETIC; QUALITY-ADJUSTED LIFE YEARS; VACCINATION;

EID: 38649085361     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2007.10.015     Document Type: Article

References (2)

1. Oxman M.N., Levin M.J., Johnson G.R., et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 352 (2005) 2271-2284
2. Hornberger J., and Robertus K. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Ann Intern Med 145 (2006) 317-325